Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
暂无分享,去创建一个
R. Wachter | A. Ducharme | M. Senni | M. Zile | W. Abraham | W. Little | E. Lovett | J. Schafer | N. Madershahian | C. Butter | M. Halbach | F. Weaver | D. Klug | J. Müller-Ehmsen | V. Swarup
[1] G. Müller,et al. Baroreflex activation therapy in patients with end-stage renal failure: proof of concept , 2015, Journal of hypertension.
[2] R. Wachter,et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy , 2015, European journal of heart failure.
[3] G. Mancia,et al. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction , 2015, Journal of hypertension.
[4] R. Wachter,et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. , 2015, JACC. Heart failure.
[5] A. Kroon,et al. Bilateral or Unilateral Stimulation for Baroreflex Activation Therapy , 2015, Hypertension.
[6] R. Wachter,et al. Impact of Baroreflex Activation Therapy on Renal Function - A Pilot Study , 2014, American Journal of Nephrology.
[7] G. Mancia,et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study , 2014, European journal of heart failure.
[8] F. Moll,et al. Carotid baroreceptors are mainly localized in the medial portions of the proximal internal carotid artery. , 2013, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.
[9] R. Wachter,et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. , 2012, Journal of the American Society of Hypertension : JASH.
[10] Karel G M Moons,et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. , 2012, Heart rhythm.
[11] G. Bakris,et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.
[12] M. Zile,et al. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. , 2011, Journal of cardiac failure.
[13] U. Hoppe,et al. Baroreflex activation as a novel therapeutic strategy for diastolic heart failure , 2011, Clinical Research in Cardiology.
[14] E. Irwin,et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[15] Robert Cody,et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. , 2006, Journal of vascular surgery.
[16] Harlan M Krumholz,et al. Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.
[17] D. Ferguson,et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. , 1989, Circulation.
[18] E. Braunwald,et al. Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. , 1968, The New England journal of medicine.